Atomo Diagnostics (ASX:AT1) secured an agreement to supply its HIV self-test kit to UK-based Newfoundland Diagnostics, valued at AU$5.4 million over five years, according to a Tuesday filing with the Australian bourse.
The agreement, running until June 30, 2030, grants Newfoundland exclusive distribution rights for the company's tests in the UK and non-exclusive rights for the EU and Colombia, the filing said.
Atomo Diagnostics shares rose nearly 6% in midday trade Tuesday.
Price (AUD): $0.02, Change: $+0.0010, Percent Change: +5.56%